{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:51:45Z","timestamp":1793317905221,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This research aimed to clarify the impact of residual ductal carcinoma in situ(DCIS) in surgical specimens obtained after neoadjuvant chemotherapy(NAC) for breast cancer on the associated prognosis outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective study was performed on a cohort of 1,009 patients who achieved pCR following NAC for breast cancer and underwent subsequent breast surgery at a single institution between January 2008 and December 2019. Overall survival, local recurrence-free survival, distant metastasis-free survival, and disease-free survival of the residual and non-residual DCIS groups were the outcomes compared, with further subgroup analysis performed according to hormone receptor status. <\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>260 individuals (25.8%) presented with residual DCIS. Based on a median follow-up of 54.0\u00a0months, no significant differences in outcomes were observed between the two groups. Patients with residual DCIS and hormone receptor-negative (HR-) breast cancer demonstrated a significant decrease in distant metastasis-free survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.030) compared to those without residual DCIS. In the HR\u2009+\u2009cohort, no significant difference was observed between the two groups. Multivariate analysis of the HR- cohort demonstrated a significant association between residual DCIS and an elevated risk for distant recurrence (hazard ratio\u2009=\u20092.3, 95% confidence interval\u2009=\u20091.01\u20135.20, <jats:italic>p<\/jats:italic>\u2009=\u20090.047).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Residual DCIS following NAC may impact breast cancer outcomes, particularly with respect to the occurrence of distant metastasis in HR- patients. Therefore, clinicians must vigilantly monitor patients with residual DCIS after NAC, and further research is needed to expand our understanding of the clinical implications of residual DCIS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12672-024-01157-z","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T10:01:58Z","timestamp":1721210518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of residual ductal carcinoma in situ with breast cancer treatment outcomes after neoadjuvant chemotherapy according to hormone receptor status"],"prefix":"10.1007","volume":"15","author":[{"given":"Eunju","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Kyung","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Il Yong","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom Seok","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Ho","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae Byul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"issue":"1","key":"1157_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejso.2021.10.016","volume":"48","author":"RAW Ploumen","year":"2022","unstructured":"Ploumen RAW, et al. The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: a nationwide retrospective study. Eur J Surg Oncol. 2022;48(1):60\u20136.","journal-title":"Eur J Surg Oncol"},{"issue":"11","key":"1157_CR2","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1001\/jamasurg.2022.4118","volume":"157","author":"M Osdoit","year":"2022","unstructured":"Osdoit M, et al. Association of residual ductal carcinoma in situ with breast cancer recurrence in the neoadjuvant I-SPY2 trial. JAMA Surg. 2022;157(11):1034\u201341.","journal-title":"JAMA Surg"},{"issue":"12","key":"1157_CR3","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S1470-2045(22)00613-1","volume":"23","author":"HM Kuerer","year":"2022","unstructured":"Kuerer HM, et al. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2022;23(12):1517\u201324.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1157_CR4","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.ejso.2019.08.001","volume":"45","author":"M Asaoka","year":"2019","unstructured":"Asaoka M, et al. Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy. Eur J Surg Oncol. 2019;45(12):2289\u201394.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"1157_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4132\/jptm.2016.10.05","volume":"51","author":"M Choi","year":"2017","unstructured":"Choi M, et al. Evaluation of pathologic complete response in breast cancer patients treated with neoadjuvant chemotherapy: experience in a single institution over a 10-year period. J Pathol Transl Med. 2017;51(1):69\u201378.","journal-title":"J Pathol Transl Med"},{"issue":"9","key":"1157_CR6","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/modpathol.2015.74","volume":"28","author":"E Provenzano","year":"2015","unstructured":"Provenzano E, et al. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol. 2015;28(9):1185\u2013201.","journal-title":"Mod Pathol"},{"issue":"1","key":"1157_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/bjc.2015.426","volume":"114","author":"A-S Hamy-Petit","year":"2016","unstructured":"Hamy-Petit A-S, et al. Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort. Br J Cancer. 2016;114(1):44\u201352.","journal-title":"Br J Cancer"},{"issue":"5","key":"1157_CR8","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1245\/s10434-015-4404-8","volume":"22","author":"P Cortazar","year":"2015","unstructured":"Cortazar P, Geyer CE. Pathological complete response in neoadjuvant treatment of breast cancer. Ann Surg Oncol. 2015;22(5):1441\u20136.","journal-title":"Ann Surg Oncol"},{"issue":"9938","key":"1157_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164\u201372.","journal-title":"Lancet"},{"issue":"15","key":"1157_CR10","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796\u2013804.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1157_CR11","doi-asserted-by":"publisher","first-page":"R65","DOI":"10.1186\/bcr2124","volume":"10","author":"P Wirapati","year":"2008","unstructured":"Wirapati P, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10(4):R65.","journal-title":"Breast Cancer Res"},{"issue":"19","key":"1157_CR12","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1200\/JCO.2006.08.2271","volume":"25","author":"C Mazouni","year":"2007","unstructured":"Mazouni C, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007;25(19):2650\u20135.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1157_CR13","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","volume":"35","author":"WF Symmans","year":"2017","unstructured":"Symmans WF, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol. 2017;35(10):1049\u201360.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1157_CR14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10549-018-4801-3","volume":"170","author":"W Haque","year":"2018","unstructured":"Haque W, et al. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat. 2018;170(3):559\u201367.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1157_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.annonc.2019.10.012","volume":"31","author":"J Heil","year":"2020","unstructured":"Heil J, et al. Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. Ann Oncol. 2020;31(1):61\u201371.","journal-title":"Ann Oncol"},{"issue":"2","key":"1157_CR16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/bjs\/znac391","volume":"110","author":"EMC Rossi","year":"2023","unstructured":"Rossi EMC, et al. Diagnostic performance of image-guided vacuum-assisted breast biopsy after neoadjuvant therapy for breast cancer: prospective pilot study. Br J Surg. 2023;110(2):217\u201324.","journal-title":"Br J Surg"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01157-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-024-01157-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01157-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T10:30:47Z","timestamp":1721212247000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-024-01157-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1157"],"URL":"https:\/\/doi.org\/10.1007\/s12672-024-01157-z","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,17]]},"assertion":[{"value":"7 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was reviewed and approved by the Institutional Review Board of the Asan Medical Center (2022-0282).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Due to the retrospective nature of this study, the patients\u2019 information remains anonymous. Therefore, informed consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"288"}}